Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL28432085 | 0.78 | ALDH1A1 (0.45) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL611061 | 0.75 | ALDH1A1 (0.35) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL2371119 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL29258016 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL28271424 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL2371120 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL2371599 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL29066588 | 0.74 | ALDH1A1 (0.38) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL1595052 | 0.74 | ALDH1A1 (0.41) | — | |
| SCHEMBL153190 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695211-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2017-07-04 | — | — | US | claimed |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2016-12-01 | — | — | US | claimed |
| US-9394333-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN (JP) | 2016-07-19 | — | — | US | claimed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | claimed |
| EP-2370451-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | Chiralgen, Ltd. (JP) | 2011-10-05 | — | — | EP | claimed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12583883-B2 | Asymmetric auxiliary group | WAVE LIFE SCIENCES LTD. (SG) | 2026-03-24 | — | — | US | disclosed |
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-05 | — | — | US | disclosed |
| US-20260055133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD (SG) | 2026-02-26 | — | — | US | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-12486505-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-12-02 | — | — | US | disclosed |
| EP-2872147-A2 | CHIRAL CONTROL | Wave Life Sciences Pte. Ltd. (SG) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872485-A1 | ASYMMETRIC AUXILIARY GROUP | WaVe Life Sciences Japan (JP) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014010250-A1 | ASYMMETRIC AUXILIARY GROUP | CHIRALGEN, LTD. (JP) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| EP-2370451-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | Chiralgen, Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, METTL3, RNASE1 | DPP4 1542/4885CHRM2 2860/4885CHRM4 2144/4885 |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | DPP4 3824/4885CHRM2 4146/4885CHRM4 4000/4885 |
| US-12583883-B2 | Asymmetric auxiliary group | AGL, RNMT, NSUN2 | DPP4 3474/4885CHRM2 1746/4885CHRM4 1627/4885 |
| US-12486505-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | DPP4 2846/4885CHRM2 4784/4885CHRM4 4692/4885 |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | DPP4 1175/4885CHRM2 4704/4885CHRM4 4014/4885 |
| US-20260055133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | NSUN2, NSUN3, NOP2 | DPP4 4435/4885CHRM2 1790/4885CHRM4 1771/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | DPP4 1671/4885CHRM2 4172/4885CHRM4 3889/4885 |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | ADAR, PNP, NUDT1 | DPP4 843/4885CHRM2 4703/4885CHRM4 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.